Search

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

EU Elections and Health Policy

HemAffairs Article #1 – June 2019

2019 will see significant changes within the European institutions.

Read more

Wiley and European Hematology Association Announce Partnership

Wiley will publish HemaSphere beginning January 2024

Hoboken, NJ, (USA) and The Hague (Netherlands) – Wiley, one of the world’s largest publishers and a global leader in research and education, today announced that it will publish the open access journal HemaSphere on…

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Hematology 2.0: navigating the world of medical apps

Interview with Dr Alex Langridge, SpR, by Dr Nuno Borges, MBBS, MRes, on behalf of YoungEHA. Despite the controversy surrounding them, medical apps remain extremely popular and lucrative endeavors.

Read more

La Cantera coaching

Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.

Read more

Hematology Education & Training

The European Hematology Association (EHA) is the largest provider of independent, evidence-based, and peer-reviewed medical and scientific education in hematology in Europe.

Read more